Creating a safer and more effective treatment for opioid use disorder using a new ibogaine analog.
Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder
['FUNDING_OTHER'] · GILGAMESH PHARMACEUTICALS INC · NIH-11043392
This study is testing a new version of ibogaine called GM-3009 to see if it can safely help people struggling with opioid addiction by easing withdrawal symptoms and supporting recovery.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GILGAMESH PHARMACEUTICALS INC (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11043392 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new synthetic version of ibogaine, called GM-3009, to treat opioid use disorder (OUD). Ibogaine has shown potential in helping individuals overcome opioid dependence, but its use has been limited due to safety concerns, particularly related to heart and brain toxicity. The research aims to conduct preclinical studies to ensure GM-3009 is safe and effective, followed by clinical trials to test its safety and efficacy in humans. Patients may benefit from a new treatment option that could help reduce withdrawal symptoms and improve abstinence rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking treatment options.
Not a fit: Patients who are not struggling with opioid use disorder or those who have contraindications to the study drug may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for individuals struggling with opioid use disorder.
How similar studies have performed: Previous research on ibogaine and its analogs has shown promise, but this specific approach with GM-3009 is novel and aims to address safety concerns.
Where this research is happening
NEW YORK, UNITED STATES
- GILGAMESH PHARMACEUTICALS INC — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAREK, GERARD JOSEPH — GILGAMESH PHARMACEUTICALS INC
- Study coordinator: MAREK, GERARD JOSEPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.